Table 2. Induction chemotherapy in patients with sinonasal malignancies with brain invasion and neurological deficits (5-FU: - 5-fluorouracil; IC: induction chemotherapy).
Induction cohort with brain invasion | Induction cohort with neurological deficits | |
---|---|---|
Induction chemotherapy agents | ||
Platinum + t axane | 6 (15%) | 4 (12.9%) |
Platinum + 5-FU | 1 (2.5%) | 3 (9.7%) |
Platinum + t axane + 5-FU | 3 (7.5%) | 2 (6.5%) |
Platinum + t axane + ifosfamide | 3 (7.5%) | 4 (12.9%) |
Platinum + e toposide | 23 (57.5%) | 15 (48.4%) |
Platinum + e toposide + ifosfamide | 1 (2.5%) | 1 (3.2%) |
Platinum + e toposide + vincristine | 1 (2.5%) | – |
Adriamycin + ifosfamide + vincristine | 1 (2.5%) | – |
Irinotecan | 1 (2.5%) | |
Platinum + t axane + cetuximab | – | 1 (3.2%) |
Platinum + t axane + gemcitabine | – | 1 (3.2%) |
Cycles of IC | Avg: 3.2 (SD: 1.4), median: 3 | Avg: 3.1 (SD: 0.9), median: 3 |
Radiographic response to induction chemotherapy | ||
Complete r esponse | 5 (12.5%) | 3 (9.7%) |
Partial r esponse | 27 (67.5%) | 19 (61.3%) |
Stable d isease | 7 (17.5%) | 6 (19.4%) |
Disease p rogression | 1 (2.5%) | 3 (9.7%) |
Interruption in i nduction c hemotherapy | 5 (12.5%) | 2 (6.5%) |
Adverse events to systemic therapy | ||
Hematologic | 9 (22.5%) | 4 (12.9%) |
Nonhematologic | 12 (30%) | 7 (22.6%) |
Abbreviation: SD, standard deviation.